Plain-English translation of NCT07215520 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new COVID-19 vaccine called that you inhale through your nose, rather than receiving as a shot in your arm. Researchers want to see if this medication is safe and causes fewer side effects than the standard COVID-19 booster vaccine. The study will compare this new nasal vaccine to the approved mRNA vaccine that many people are already familiar with.
Current COVID-19 vaccines work well but some people experience side effects or prefer not to get shots. This medication is designed to provide protection against COVID-19 while potentially being more comfortable to receive and causing fewer unwanted reactions.
If you are enrolled, you will be randomly assigned to receive either the new nasal vaccine plus a placebo injection, or a placebo nasal spray plus the standard COVID-19 booster shot in your arm. You will not know which group you are in (that's the 'double-blind' part). You will need to attend study visits, likely including a screening visit, a vaccination visit, and follow-up visits to check for any side effects or reactions. The study will monitor your safety and ask about how you are feeling after vaccination.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
CastleVax Inc.
Enrollment target
~200 participants
Started
November 2025
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.